Jim Mullen scours pri­vate eq­ui­ty deals amid biotech win­ter; Ex-Ab­b­Vie med­ical chief suc­ceeds Brig­gs Mor­ri­son at Syn­dax

Jim Mullen is in, by his count, his third or fourth “long, cold win­ter in biotech in­vest­ing.” But that’s not stop­ping the ex-Bio­gen CEO from find­ing flick­ers of light.

Ear­li­er this week, pri­vate eq­ui­ty play­er Ad­vent In­ter­na­tion­al an­nounced that Mullen had joined as an op­er­at­ing part­ner — its term for in­de­pen­dent ad­vi­sors who bring in­dus­try ex­pe­ri­ence.

Mullen told End­points News in an in­ter­view that he’s been do­ing ad­vis­ing work for a num­ber of pri­vate eq­ui­ty firms and en­joyed it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER